A COMPARISON OF GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2: A SYSTEMATIC REVIEW

Main Article Content

Dr Rida Rizvi
Dr Ashutosh Roy
Dr Renju Ravi
Dr Jyothi Vybhavi V S

Keywords

Diabetes, GLP-1, DPP-4, Blood sugar, Receptor

Abstract

Introduction: Decisions on balancing use of GLP-1 receptor agonists or DPP-4 inhibitors depend on various factors like patient's own characteristics and choice, in addition to medical background. GLP- 1 receptor agonists and DPP-4 inhibitor are a class of medications that work on incretin system to normoglycemia.


Aims and Objectives: To compare the effectiveness of drugs for the treatment of type 2 diabetes: GLP-1 receptor agonists Vs DPP-4 inhibitors.


Methods: A search of the MEDLINE databases restricted to human clinical trials using the search terms 'GLP-1RA' or 'DPP-4 inhibitor' produced seven direct comparative studies and one post hoc analysis all comparing a GLP-1RA with sitagliptin. The effectiveness and safety of GLP-1RAs and DPP-4 inhibitors in T2D patients was assessed by use of a variety of tools including research studies, treatment algorithms, product prescribing information, and personal clinical experience.


Results: For GLP-1RAs, direct clinical trials showed superior control of blood sugar levels, weight reduction, and general drug approach compared to sitagliptin: the DPP-4 inhibitions through these medications, rarely, consumers experience side effects like nausea. However, with a proper education and threat, dosage increase could manage it, though. The nausea is momentarily. From a nutshell, the existing treatment guidelines make an increment over metformin medication with a switch to an incretin-based agent for further reducing the cardiovascular risk in those patients who are already on the treatment, but this use remains restricted in some countries.


Conclusion: GLP-1RAs give a better glucose control and weight loss in T2D than DPP-4 inhibitors. Alternatives are DPP-4 inhibitors instead of GLP-1RAs in situations of no prominent weight changes, when formulation by mouth is necessary or only well-tolerated GLP-1RAs are available.

Abstract 176 | pdf Downloads 89

References

1. A. M. Ahmed, “History of diabetes mellitus,” Saudi Med J, vol. 23, no. 4, pp. 373–378, 2002, [Online]. Available: https://www.researchgate.net/
2. C. O. Osborn, “Type 1 and Type 2 Diabetes: What’s the Difference?,” 2022, [Online]. Available: https://www.healthline.com/
3. M. Patlak, “New Weapons to Combat an Ancient Disease,” FASEB J, vol. 16, no. 14, 2002, [Online]. Available: https://www.margiepatlak.com/
4. S. Liu et al., “Neutrophil-to-lymphocyte ratio is associated with diabetic peripheral neuropathy in type 2 diabetes patients,” Diabetes Res. Clin. Pract., vol. 130, pp. 90–97, Aug. 2017, doi: 10.1016/j.diabres.2017.05.008.
5. S. Tsalamandris et al., “The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives,” Eur. Cardiol. Rev., vol. 14, no. 1, pp. 50–59, Apr. 2019, doi: 10.15420/ecr.2018.33.1.
6. A. D. Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, vol. 27, no. suppl_1, pp. s5–s10, Jan. 2004, doi: 10.2337/diacare.27.2007.S5.
7. C. Weyer, C. Bogardus, D. M. Mott, and R. E. Pratley, “The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus,” J. Clin. Invest., vol. 104, no. 6, pp. 787–794, Sep. 1999, doi: 10.1172/JCI7231.
8. M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” Lancet, vol. 365, no. 9467, pp. 1333–1346, Apr. 2005, doi: 10.1016/S0140-6736(05)61032-X.
9. S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 diabetes,” Lancet, vol. 389, no. 10085, pp. 2239–2251, Jun. 2017, doi: 10.1016/S0140-6736(17)30058-2.
10. B. Zhou et al., “Worldwide trends in diabetes since 1980: a pooled analysis of 751 population- based studies with 4·4 million participants,” Lancet, vol. 387, no. 10027, pp. 1513–1530, Apr. 2016, doi: 10.1016/S0140-6736(16)00618-8.

11. M. Prelipcean, “Behind the counter: Glucagon-like peptide-1 receptor agonists for type 2 diabetes,” 2020, [Online]. Available: https://www.medicalnewstoday.com/
12. W. Latif, K. J. Lambrinos, and R. Rodriguez., “Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs),” 2023, [Online]. Available: https://www.ncbi. nlm.nih.gov/
13. B. Cervoni, “GLP-1 Receptor Agonists for Type 2 Diabetes,” 2023, [Online]. Available: https://www.verywellhealth.com/
14. S. W. Lim, J. Z. Jin, L. Jin, J. Jin, and C. Li, “Role of dipeptidyl peptidase-4 inhibitors in new- onset diabetes after transplantation,” Korean J. Intern. Med., vol. 30, no. 6, pp. 759–770, Oct. 2015, doi: 10.3904/kjim.2015.30.6.759.
15. B. Charbonnel, A. Karasik, J. Liu, M. Wu, and G. Meininger, “Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone,” Diabetes Care, vol. 29, no. 12, pp. 2638–2643, Dec. 2006, doi: 10.2337/dc06-0706.
16. E. Bosi, R. P. Camisasca, C. Collober, E. Rochotte, and A. J. Garber, “Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin,” Diabetes Care, vol. 30, no. 4, pp. 890–895, Apr. 2007, doi: 10.2337/dc06-1732.
17. R. A. DeFronzo et al., “The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone,” Diabetes Care, vol. 32, no. 9, pp. 1649–1655, Sep. 2009, doi: 10.2337/dc08-1984.
18. K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, and P. Stein, “Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin,” Diabetes, Obes. Metab., vol. 9, no. 5, pp. 733–745, Sep. 2007, doi: 10.1111/j.1463-1326.2007.00744.x.
19. J. Rosenstock, R. Brazg, P. J. Andryuk, K. Lu, and P. Stein, “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study,” Clin. Ther., vol. 28, no. 10, pp. 1556–1568, Oct. 2006, doi: 10.1016/j.clinthera
.2006.10.007.
20. A. J. Garber, A. Schweizer, M. A. Baron, E. Rochotte, and S. Dejager, “Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study*,” Diabetes, Obes. Metab., vol. 9, no. 2, pp. 166–174, Mar. 2007, doi: 10.1111/j.1463-1326.2006.00684.x.
21. L. Kennedy and J. A. Davidson, “Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors,” Cleve. Clin. J. Med., vol. 76, no. 12 suppl 5, pp. S28–S38, Dec. 2009, doi: 10.3949/ccjm.76.s5.05.
22. J. Gerich, “DPP-4 inhibitors: What may be the clinical differentiators?,” Diabetes Res. Clin. Pract., vol. 90, no. 2, pp. 131–140, Nov. 2010, doi: 10.1016/j.diabres.2010.07.006.
23. R. A. DeFronzo, T. Okerson, P. Viswanathan, X. Guan, J. H. Holcombe, and L. MacConell, “Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study,” Curr. Med. Res. Opin., vol. 24, no. 10, pp. 2943–2952, Oct. 2008, doi: 10.1185/03007990802418851.
24. J. K. Berg, S. K. Shenouda, C. R. Heilmann, A. L. Gray, and J. H. Holcombe, “Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover study,” Diabetes, Obes. Metab., vol. 13, no. 11, pp. 982– 989, Nov. 2011, doi: 10.1111/j.1463-1326.2011.01428.x.
25. R. M. Bergenstal et al., “Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial,” Lancet, vol. 376, no. 9739, pp. 431–439, Aug. 2010, doi: 10.1016/S0140-
6736(10)60590-9.
26. C. Wysham et al., “DURATION‐2: efficacy and safety of switching from maximum daily

sitagliptin or pioglitazone to once‐weekly exenatide,” Diabet. Med., vol. 28, no. 6, pp. 705–714, Jun. 2011, doi: 10.1111/j.1464-5491.2011.03301.x.
27. R. E. Pratley et al., “Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open- label trial,” Lancet, vol. 375, no. 9724, pp. 1447–1456, Apr. 2010, doi: 10.1016/S0140-6736
(10)60307-8.
28. R. Pratley et al., “One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial,” Int. J. Clin. Pract., vol. 65, no. 4, pp. 397–407, Apr. 2011, doi: 10.1111/j.1742-1241.2011.02656.x.
29. R. E. Pratley et al., “Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes,” Diabetes Care, vol. 35, no. 10, pp. 1986–1993, Oct. 2012, doi: 10.2337/dc11-2113.
30. M. Davies, R. E. Pratley, E. Montanya, and A. Thomsen, “Liraglutide Reduces A1c to a Greater Extent Than Sitagliptin Regardless of Baseline A1c Levels,” 2010, [Online]. Available: https://www.researchgate.net/
31. A. B. King et al., “Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0%,” Endocr. Pract., vol. 19, no. 1, pp. 64–72, Jan. 2013, doi: 10.4158/EP12232.OR.
32. M. J. Abrahamson et al., “Aace Comprehensive Diabetes Management Algorithm 2013,” Endocr. Pract., vol. 19, no. 2, pp. 327–336, Mar. 2013, doi: 10.4158/endp.19.2.a38267720403k242.
33. S. E. Inzucchi et al., “Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach,” Diabetes Care, vol. 35, no. 6, pp. 1364–1379, Jun. 2012, doi: 10.2337/dc12-0413.
34. N. I. for H. and C. Excellence, “Clinical guideline 87, the management of type 2 diabetes.,” 2009, [Online]. Available: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf
35. N. I. for H. and C. Excellence, “Final appraisal determination: Liraglutide for the treatment of type 2 diabetes mellitus.,” 2010, [Online]. Available: http://www.nice.org.uk/nicemedia
/live/11895/50663/50663.pdf
36. H. W. Rodbard et al., “Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,” Endocr. Pract., vol. 15, no. 6, pp. 540–559, Sep. 2009, doi: 10.4158/EP.15.6.540.
37. Sanofi-aventis., “Lixisenatide SPC: Lixisenatide summary of product characteristics.,” 2013, [Online]. Available: https://ec.europa.eu/health/documents/community-register/2013/201302 01125120/anx_125120_en.pdf
38. A. Pharmaceuticals, “Byetta SPC,” 2013.
39. N. Nordisk, “Victoza SPC,” 2012, [Online]. Available: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf
40. N. Nordisk., “Victoza PI,” 2024, [Online]. Available: http://www.novo-pi.com/victoza.pdf
41. A. Pharmaceuticals, “Bydureon PI,” 2024, [Online]. Available: http://documents.bydureon.com
/Bydureon_PI.pdf
42. A. Pharmaceuticals, “Bydureon SPC,” 2024, [Online]. Available: http://www.ema.europa.eu
/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002020/WC500108241.pdf
43. A. Pharmaceuticals, “Byetta PI,” 2024, [Online]. Available: http://documents.byetta. com/ Byetta_PI.pdf
44. M. Sharp and D. Corp, “Januvia SPC,” 2024, [Online]. Available: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000722/WC500039054.pdf
45. B.-M. Squibb, “Onglyza SPC,” 2024, [Online]. Available: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf

46. B.-M. Squibb, “Onglyza PI,” 2024, [Online]. Available: http://packageinserts.bms.com
/pi/pi_onglyza.pdf
47. Novartis, “Galvus SPC,” 2024, [Online]. Available: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf
48. I. Boehringer Ingelheim Pharmaceuticals, “Trajenta SPC.,” 2024, [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002110/WC500115745.pdf
49. I. Boehringer Ingelheim Pharmaceuticals, “Trajenta PI,” 2024, [Online]. Available: http://bidocs.boehringer- ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Inf ormation/PIs/Tradjenta/Tradjenta.pdf
50. K. Nakatani et al., “Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin,” Diabetes Ther., 2012, doi: 10.1007/s13300-012-0014-7.
51. M. A. Nauck, “A Critical Analysis of the Clinical Use of Incretin-Based Therapies,” Diabetes Care, vol. 36, no. 7, pp. 2126–2132, Jul. 2013, doi: 10.2337/dc12-2504.
52. R. A. Noel, D. K. Braun, R. E. Patterson, and G. L. Bloomgren, “Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes,” Diabetes Care, vol. 32, no. 5, pp. 834–838, May 2009, doi: 10.2337/dc08-1755.
53. A. E. Butler, M. Campbell-Thompson, T. Gurlo, D. W. Dawson, M. Atkinson, and P. C. Butler, “Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors,” Diabetes, vol. 62, no. 7, pp. 2595–2604, Jul. 2013, doi: 10.2337/db12-
1686.
54. S. E. Kahn, “Incretin Therapy and Islet Pathology: A Time for Caution,” Diabetes, vol. 62, no. 7, pp. 2178–2180, Jul. 2013, doi: 10.2337/db13-0520.
55. F. and D. Administration, “FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes,” 2024, [Online]. Available: http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
56. B. M. Scirica et al., “Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus,” N. Engl. J. Med., vol. 369, no. 14, pp. 1317–1326, Oct. 2013, doi: 10.1056/NEJMoa1307684.
57. W. B. White et al., “Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes,” N. Engl. J. Med., vol. 369, no. 14, pp. 1327–1335, Oct. 2013, doi: 10.1056/NEJMoa1305889.
58. A. López-Ruiz et al., “Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers,” Pharm. World Sci., 2010, doi: 10.1007/s11096-010-9423-8.
59. Y. Kaakeh, S. Kanjee, K. Boone, and J. Sutton, “Liraglutide‐Induced Acute Kidney Injury,” Pharmacother. J. Hum. Pharmacol. Drug Ther., vol. 32, no. 1, Jan. 2012, doi: 10.1002/PHAR.1014.
60. H. Nandakoban, T. J. Furlong, and J. R. Flack, “Acute tubulointerstitial nephritis following treatment with exenatide,” Diabet. Med., vol. 30, no. 1, pp. 123–125, Jan. 2013, doi: 10.1111/j.1464-5491.2012.03738.x.
61. W. J. Weise, M. S. Sivanandy, C. A. Block, and R. J. Comi, “Exenatide-Associated Ischemic Renal Failure,” Diabetes Care, vol. 32, no. 2, pp. e22–e23, Feb. 2009, doi: 10.2337/dc08-1309.
62. B. M. Kuehn, “Exenatide and Kidney Function,” JAMA, vol. 302, no. 24, p. 2644, Dec. 2009, doi: 10.1001/jama.2009.1847.
63. M. E. J. Lean, J. K. Powrie, A. S. Anderson, and P. H. Garthwaite, “Obesity, Weight Loss and Prognosis in Type 2 Diabetes,” Diabet. Med., vol. 7, no. 3, pp. 228–233, Mar. 1990, doi: 10.1111/j.1464-5491.1990.tb01375.x.

64. L. S. Aucott, “Influences of weight loss on long-term diabetes outcomes,” Proc. Nutr. Soc., vol. 67, no. 1, pp. 54–59, Feb. 2008, doi: 10.1017/S0029665108006022.
65. K. Fujioka, “Benefits of moderate weight loss in patients with type 2 diabetes,” Diabetes, Obes. Metab., vol. 12, no. 3, pp. 186–194, Mar. 2010, doi: 10.1111/j.1463-1326.2009.01155.x.
66. J. R. Ussher and D. J. Drucker, “Cardiovascular Biology of the Incretin System,” Endocr. Rev., vol. 33, no. 2, pp. 187–215, Apr. 2012, doi: 10.1210/er.2011-1052.
67. M. Davies, R. Pratley, M. Hammer, A. B. Thomsen, and R. Cuddihy, “Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin,” Diabet. Med., vol. 28, no. 3, pp. 333–337, Mar. 2011, doi: 10.1111/j.1464- 5491.2010.03074.x.
68. J. H. Best et al., “Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment,” Diabetes Care, vol. 34, no. 2, pp. 314–319, Feb. 2011, doi: 10.2337/dc10- 1119.